August 19, 2009

Angiotech's Option IVC Filter Launched in US

August 20, 2009—Angiotech Pharmaceuticals, Inc. (Vancouver, BC) announced the commercial launch of the Option inferior vena cava (IVC) filter in the United States. This comes after receipt of 510(k) marketing clearance by the US Food and Drug Administration in June and a limited prelaunch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC filter, which it obtained in a license agreement with privately held Rex Medical, LP (Conshohocken, PA) as announced in March 2008. The Option IVC Filter is interventionally implanted for the prevention of recurrent pulmonary embolism. The device is specifically designed for use as both a permanent or temporary implant.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

August 19, 2009

Angiotech's Option IVC Filter Launched in US

Current Issue

Keep In Touch